TARGET 2.0 Study: Safety and Performance of the Cardiovalve TR Replacement System

Official title

TARGET 2.0 Study: Safety and Performance of the Cardiovalve Tricuspid Valve Replacement System in the Treatment of Subjects With Tricuspid Regurgitation- Investigation

Overview

This investigation is a continuation for "TARGET" investigation and its purpose is to further demonstrate the efficiency and safety of the Cardiovalve system in the treatment of subjects with tricuspid regurgitation. The same subject population will be included, while applying the clinical and scientific knowledge accumulated in the TARGET investigation. This investigation will support the submission for obtaining marketing approval.

Detailed description

"TARGET 2.0": Safety and Performance of the Cardiovalve Tricuspid valve replacement system in the treatment of subjects with tricuspid regurgitation- investigation: Cardiovalve Tricuspid Valve Replacement system (hereinafter referred to as Cardiovalve TR system) The system has not been granted CE mark at this time The Cardiovalve implant consists of three bovine pericardium tissue leaflets, self-expanding dual nitinol frame, and fabric. A total of 24 anchoring points affix the device to the native tricuspid annulus.

The Delivery System is intended to deliver the valve in the crimped position via the transfemoral venous approach. It comprises of a catheter assembly and handles. The handles knobs facilitate valve alignment and positioning in the native valve, and control the capsule expansion and release of the Cardiovalve implant.

The Cardiovalve TR Valve Replacement System is intended for reduction of tricuspid regurgitation (TR) in patients with symptomatic severe or greater secondary tricuspid regurgitation despite being treated with medical therapy for whom tricuspid valve replacement is deemed appropriate by a Heart Team. The system percutaneously delivers the Implant to the tricuspid valve via femoral vein access This investigation is a continuation for "TARGET" investigation and its purpose is to further demonstrate the efficiency and safety of the Cardiovalve system in the treatment of subjects with tricuspid regurgitation. The same subject population will be included, while applying the clinical and scientific knowledge accumulated in the TARGET investigation. This investigation will support the submission for obtaining marketing approval.

Interventions

• Device Cardiovalve TR valve replacement System
  Cardiovalve Tricuspid Valve Replacement system

Primary outcome measures

• Freedom from device or procedure-related adverse events [Time frame: 30 days]
• Reduction in TR grade [Time frame: 30 days]

Secondary outcome measures (2)

• Six minute walk test [Time frame: 30 days, 6 months, 12 months, annual for five years]
• KCCQ [Time frame: 30 days, 6 months, 12 months, annual for five years]

Eligibility criteria

Inclusion criteria

• Subject is ≥ 18 and <85 years
• Severe tricuspid regurgitation (TR) ≥3+ based upon echocardiography, as assessed by independent core laboratory using a 5-grade classification (mild (1), moderate (2), severe (3), massive (4), torrential (5)). Trace and no TR is considered 0)29
• Symptomatic, NYHA Class II-IV
• Left ventricular ejection fraction (LVEF) ≥ 30%
• Subject adequately treated based upon medical standards
• Subjects are at high risk for open heart surgery
• Subject provided written, informed consent before investigation enrollment
• Subject approved by the Subject Screening Committee

Anatomical Inclusion Criteria (measured by CT)

• Right femoral vein diameter > 9mm
• Tricuspid valve diameter < 55 mm
• RV length > 45 mm

Exclusion criteria

Subjects will be excluded from the investigation if fulfill any of the following criteria:

• Cardiac anatomy deemed not suitable for the Cardiovalve TR system as evaluated (by CT)
• Venous peripheral anatomy or any spinal anatomy that is unsuitable for Cardiovalve TR implant delivery (by CT)
• Primary tricuspid disease that may interfere with Cardiovalve implantation
• Severe right ventricular failure (by Echo core lab adjudication)
• Significant coronary artery disease requiring percutaneous or surgical intervention
• Severe systolic pulmonary arterial pressure, pASP > 2/3 systemic BP with PVR > 5 Wood units after vasodilator challenge
• Presence of any known life threatening non-cardiac disease that will limit the subject's life expectancy to less than one year
• Cerebrovascular event (stroke, TIA) within the past 3 months
• Active endocarditis or history of mitral/tricuspid endocarditis within 3 months or infection requiring antibiotic within 2 weeks before index procedure
• Subject has significant other sided valvular heart disease which requires treatment (e.g. mitral regurgitation or stenosis, or aortic regurgitation or stenosis)
• Documented primary coagulopathy or platelet disorder, including thrombocytopenia (absolute platelet count <90k)
• Documented evidence of significant renal dysfunction (eGFR<30 ml/min/1.73m2) or any form of dialysis at time of screening within 30 days
• Untreatable hypersensitivity or contraindication to any of the following: all antiplatelets, all anticoagulants, nitinol alloys (nickel and titanium), bovine tissue, glutaraldehyde, contrast media, or Polyethylene Glycol (PEG)
• Subjects unsuitable for implantation due to thrombosis of the lower venous system or presence of a vena cava filter
• Evidence of an acute myocardial infarction (AMI) ≤ 1 month (30 days)
• Liver cirrhosis > Child-Pugh Class A
• Psychiatric or behavioral disease including known alcohol or drug abuser that is likely to impair compliance with protocol
• Pregnant, lactating or planning pregnancy within next 12 months
• Requirement for antibiotic treatment within the last 48 hours
• Surgical or interventional procedure planned within 30 days prior to index procedure
• Refractory heart failure requiring advanced intervention (i.e. left ventricular assist device, transplantation) or UNOS Status 1 heart transplant or prior orthotropic heart transplantation.
• Prior Tricuspid valve surgery or transcatheter tricuspid valve procedure that may interfere with the Cardiovalve device. Valve in a valve procedure is excluded.
• Modified Rankin Scale > 4 disability
• Implant or revision of any rhythm management device (CRT or CRT-D) or implantable cardioverter-defibrillator within 30 days prior to index procedure
• Acutely decompensated heart failure (i.e. hemodynamically unstable or requiring IV inotrope) at the time of screening
• Severe COPD or continuous use of home oxygen
• Hgb < 9 g/dL at screening
• The subject has contraindication against a transesophageal echo (TEE) during the procedure that cannot be replaced by other imaging.
• Currently participating in an investigational drug or another device investigation which has not reached its primary endpoint
• Subjects with >2 leads or with any lead that may interfere with Cardiovalve procedure or device

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

Germany · 1 center

• Uniklinik Bonn - — Bonn

Identifiers

NCT: NCT07334691 · CP 25-01

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗